Company Description
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors.
The company’s lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 1 clinical trial to treat glioblastoma.
It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in Phase 1 clinical trial.
In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage.
The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018.
Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2014 |
| IPO Date | Jan 30, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 24 |
| CEO | Mark Velleca |
Contact Details
Address: One Main Street, 14th Floor Cambridge, Massachusetts 02142 United States | |
| Phone | 617 252 0848 |
| Website | blackdiamondtherapeutics.com |
Stock Details
| Ticker Symbol | BDTX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $19.00 |
| CIK Code | 0001701541 |
| CUSIP Number | 09203E105 |
| ISIN Number | US09203E1055 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Mark A. Velleca M.D., Ph.D. | Chief Executive Officer, President and Chairman |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 18, 2025 | ARS | Filing |
| Apr 18, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 18, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 21, 2025 | SCHEDULE 13G/A | Filing |
| Mar 19, 2025 | 8-K | Current Report |
| Mar 6, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 6, 2025 | 10-K | Annual Report |
| Mar 6, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |